fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Multiple Doses of AU-011 are Well-Tolerated, with Vision Preservation Observed at 12 to 18 Months All Patients Met Preliminary Efficacy Endpoint to Date with Evidence of Biological Activity CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that updated clinical data from its Phase 1b/2...
23RD OCTOBER 2018 EB8018, the lead investigational candidate, targets Crohn’s disease with potential for other GI disorders Paris, France and Cambridge, MA, USA – October 23, 2018 ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion...
Palma, Spain and San Diego, USA, 23 October, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical...
25 independent distributors contracted Total of 512 distributor reps now selling CERAMENT BVF New distribution network will positively impact North American reported sales and net margins   Lund, Sweden, 08:00 CET, 22 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, announces that it has started selling CERAMENT® BVF...
Cambridge, UK and Indianapolis, US – 15 October 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”) provides an update following receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in respect of its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) on 5 October 2018. “Our discussions...
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October Only issue raised relates to FDA inspection of contract manufacturer of active ingredient No other quality or manufacturing deficiencies noted No clinical safety or efficacy issues identified and no requirement for further clinical studies or data analyses Conference call scheduled for 09.30...
Lund, Sweden, 08:00 CET, 08 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces that its US commercial team will be showcasing CERAMENT®|BONE VOID FILLER (CERAMENT®|BVF) at two important US orthopedic conferences taking place in October. These marketing activities are taking place just ahead of the launch...
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients...
Lund, Sweden, 18:00 CET 28 September 2018 – During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 September 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,555,917. For more information contact: BONESUPPORT AB Emil...
1 2 3 4 5 48

Lundbeckfonden Ventures

Nyheder

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
4. februar 2019
BONESUPPORT and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting
1. februar 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
29. januar 2019